Cardinal Health (CAH) Is More Than a Low-Margin Drug Distributor – Alphastreet

Why Cardinal Health shouldn’t be judged as a easy wholesaler

Cardinal Health (CAH) is straightforward to dismiss if traders cease on the headline description. Drug distribution is a scale enterprise with skinny margins, working-capital depth, and fixed reimbursement strain. However that shorthand misses how Cardinal’s portfolio has been evolving. The corporate nonetheless depends on distribution scale, but its earnings profile more and more is determined by specialty prescribed drugs, companies, and a set of development companies that make the enterprise greater than a plain wholesaler.

The third quarter of fiscal 2026 made that distinction clearer. Income elevated 11% 12 months over 12 months to $60.9 billion, whereas non-GAAP working earnings rose 18% to $956 million and non-GAAP diluted EPS elevated 35% to $3.17. GAAP working earnings fell 30% to $509 million, however the launch tied that to a $184 million pre-tax goodwill impairment cost within the GMPD section. The hole between GAAP and non-GAAP outcomes is a reminder that traders must separate underlying working momentum from one-time accounting noise.

How pharmaceutical scale and development companies assist the mannequin

The core of the story stays the Pharmaceutical and Specialty Options section, however Cardinal is now not solely about transferring commodity drug volumes. In fiscal 2025, the Pharma section generated $204.6 billion of income, whereas the World Medical Merchandise and Distribution section generated $12.6 billion and the Different section generated $5.4 billion, with development in at-House Options, Nuclear and Precision Health Options, and OptiFreight Logistics. That blend issues as a result of it provides Cardinal a number of methods to construct earnings past fundamental distribution spreads.

The quarter strengthened that time. Pharmaceutical and Specialty Options section revenue elevated 14% to $784 million within the third quarter of fiscal 2026, helped by branded and specialty pharmaceutical merchandise and contributions from current acquisitions, in accordance with the earnings launch. Against this, World Medical Merchandise and Distribution section revenue fell 36% to $25 million and income was flat at $3.1 billion, displaying that not each enterprise line is contributing evenly in the meanwhile.

That unevenness is definitely a part of the thesis. Cardinal’s higher companies don’t want each section to be sturdy on the identical time if the upper-high quality items proceed to develop. Administration mentioned within the annual report that the Different section contains companies similar to Nuclear and Precision Health Options, at-House Options, and OptiFreight Logistics. These adjacencies matter as a result of they sit nearer to specialty care, logistics coordination, and healthcare companies the place relationships and capabilities may be extra differentiated than in conventional wholesale distribution.

Why money deployment and earnings high quality matter

Traders also needs to take note of what Cardinal is doing with the money the mannequin generates. In the course of the 9 months ended March 31, 2026, web money offered by working actions was $3.5 billion, even after together with $417 million of opioid-litigation funds. Over the identical interval, the corporate deployed $1.9 billion for the Solaris Health acquisition, repaid $600 million of debt, repurchased $1.0 billion of shares, paid $371 million in dividends, and spent $385 million on capital expenditures.

That’s a lot of stability-sheet exercise, and it explains why leverage nonetheless deserves monitoring. At March 31, 2026, Cardinal had $3.9 billion of money and equivalents, whole property of $56.689 billion, and whole lengthy-time period obligations together with the present portion and different quick-time period borrowings of $8.9 billion. But it surely additionally reveals administration is actively reshaping the corporate slightly than merely defending the legacy distribution base.

The annual baseline can also be higher than the low-margin label implies. For fiscal 2025, Cardinal generated $222.6 billion of income, $2.275 billion of GAAP working earnings, and $2.786 billion of non-GAAP working earnings. These figures don’t flip the corporate into a software program enterprise, however they do present a big platform with significant earnings energy when combine improves.

What traders ought to watch subsequent throughout specialty development, margins, and capital allocation

The largest query is whether or not Pharmaceutical and Specialty Options can preserve driving revenue development quick sufficient to outweigh volatility in GMPD and different transferring items. If branded and specialty pharmaceutical demand, acquisition contributions, and development companies preserve increasing, Cardinal’s earnings combine ought to progressively look higher than its income combine suggests.

Traders also needs to watch whether or not administration retains balancing acquisitions, debt discount, and buybacks with out overreaching. The corporate raised and narrowed fiscal 2026 non-GAAP EPS steering to $10.70 to $10.80 after the third-quarter report, which suggests administration nonetheless sees wholesome underlying momentum. If that confidence is matched by disciplined capital deployment, Cardinal can proceed to rerate as a healthcare-companies platform as a substitute of a plain distributor.

Key Alerts for Traders

• Third-quarter fiscal 2026 income elevated 11% to $60.9 billion, whereas non-GAAP working earnings rose 18% to $956 million.
• Pharmaceutical and Specialty Options section revenue elevated 14% to $784 million within the third quarter of fiscal 2026.
• In the course of the first 9 months of fiscal 2026, Cardinal generated $3.5 billion of working money move and repurchased $1.0 billion of inventory.
• Fiscal 2025 income was $222.6 billion, with non-GAAP working earnings of $2.786 billion.
• Administration raised and narrowed fiscal 2026 non-GAAP EPS steering to $10.70 to $10.80 after the third-quarter report.

Sources

1. https://www.sec.gov/Archives/edgar/knowledge/721371/000072137126000017/a26q3_x033126xex991xnewsre.htm
2. https://www.sec.gov/Archives/edgar/knowledge/721371/000072137126000018/cah-20260331.htm
3. https://www.sec.gov/Archives/edgar/knowledge/721371/000072137125000079/cah-20250630.htm